Source comparison
CJC-1295 No DAC & Ipamorelin Work: Comparison of Mechanisms and Applications
Understanding the mechanistic differences between CJC-1295 no DAC and Ipamorelin helps researchers select the appropriate peptide or combination for specific experimental questions. The table below compares their receptor targets, pharmacokinetics, and typical
This comparison does not assign a generated winner or score.
- Understanding the mechanistic differences between CJC-1295 no DAC and Ipamorelin helps researchers select the appropriate peptide or combination for specific experimental questions. The table below compares their receptor targets, pharmacokinetics, and typical research applications.
- CJC-1295 no DAC
- GHRH receptor (pituitary somatotrophs)
- ~30 minutes
- 30–60 minutes post-injection, returns to baseline in 2–3 hours
- Pulsatile GH dynamics, circadian rhythm studies, dose-timing optimization
- Best for short-duration pulses mimicking natural GHRH signaling—ideal when precise temporal control matters
- Ipamorelin
- GHS-R1a (ghrelin receptor)
- ~2 hours
- 30–45 minutes post-injection, elevated 3–4 hours
- Body composition studies, aging models, appetite-independent GH stimulation
- Best for selective GH release without cortisol or prolactin elevation—ideal for metabolic and longevity research
- CJC-1295 no DAC + Ipamorelin (combination)
- GHRH receptor + GHS-R1a
- Variable (staggered clearance)
- 30–45 minutes, amplitude 2.5–4× higher than single agent
- Synergistic GH response studies, muscle hypertrophy models, fat loss investigations
- Best for maximizing GH pulse amplitude through dual-pathway stimulation—most reproducible results in body composition research
- CJC-1295 with DAC
- GHRH receptor (with albumin binding for extended half-life)
- 6–8 days
- Sustained elevation over days, blunted pulsatility
- Continuous GH elevation models, long-duration studies with infrequent dosing
- Best for sustained GH exposure—but loses pulsatile signaling benefits and increases desensitization risk over time